InGeNA brings together industry expertise and consumer experience to develop practical solutions, inform national policy, and accelerate the adoption of genomics and precision medicine.

InGeNA keeps members informed about government priorities, policy developments, and emerging opportunities. Members contribute technical expertise and practical insight into how these developments will affect the genomics sector, healthcare delivery, and patients.

InGeNA represents the industry directly on government and sector advisory bodies.

Our CEO, Dr Erin Evans, currently sits on:

• Genomics Australia Advisory Committee, as an independent industry member
• Queensland Health Genomics Engagement Group

Through our Policy Working Group, Data Working Group and Consumer Advisory Group, InGeNA turns government intelligence, member expertise and consumer experience into practical advocacy and sector initiatives.

Our 2025 Annual Report records 11 submissions and representations to federal and state policy processes. This work has continued in 2026 through submissions on the Federal Budget, the Medical Research Future Fund and epilepsy in Australia.

Current priorities and projects include:

• Keeping members informed about government policy, funding, regulatory, and implementation developments.
• Bringing member and consumer perspectives back to government through submissions, meetings, briefings and roundtables.
• Advocating for an Australian National Genomics Test Directory to improve access to appropriate genomic testing.
• Contributing to national genomics policy, health technology assessment, research funding, cancer control and genetic discrimination reform.
• Developing an emerging Digital Genomics Maturity Model to identify the capabilities, standards and investment required to scale genomic data and infrastructure.
• Supporting national work to improve therapeutic recommendations and clinical trial information in somatic oncology genomic reports

This approach gives members early insight into developments affecting the sector and a meaningful opportunity to shape InGeNA’s response. It also gives government access to a collective perspective spanning diagnostics, pathology, therapeutics, data, technology, services, and clinical implementation.

Our 2025 Policy Position Statement, Advancing Genomic Medicine in Australia, sets out what we are asking government to do. It calls for universal access to comprehensive genomic profiling for all cancer patients within five years. It also calls for moving proven research into routine clinical care, establishing a national genomic test directory, and building sustainable funding into national health agreements.

InGeNA’s current work builds on a substantial body of evidence and sector leadership developed since 2020. Major contributions include:

• Genomic Data in Australia, an industry-led review of genomic data sharing, governance and standards.
• Valuing the Impact of Genomics on Healthcare in Australia, developed with Deloitte Access Economics.
• The Precision Medicine Workforce Competency Framework.
• Realising the Full Potential of Genomics to Personalise Healthcare, focused on health technology assessment and equitable access.
• The 2022 Precision Health Roundtable, bringing together industry, government, healthcare, research and consumers.
• Australia Thinks Genomics, a resource covering national and jurisdictional genomics strategies.

This foundation continues to shape InGeNA’s advocacy today.

See all submissions    See all publications

Highlights from InGeNA’s advocacy calendar, updated as events are confirmed.

Read all news     See all events